DNA-activated PARPs, particularly PARP1, became attractive drug target candidatesfor cancer therapy in 2005 when PARP inhibition (PARPi) was shown to inducesynthetic lethality in cells lacking BRCA1/2 (Bryant et al., 2005; Farmer et al., 2005). This evidence concerns the gene PARP1 and cancer.